Skip to main content

Day: June 5, 2020

Mid-Con Energy Partners, LP Completes Strategic Recapitalization, Changes in Governance, Redetermination of Its Borrowing Base, and Selection of New Operator

TULSA, June 05, 2020 (GLOBE NEWSWIRE) — Mid-Con Energy Partners, LP (NASDAQ: MCEP) (“Mid-Con” or the “Partnership”) has entered into a strategic recapitalization transaction with its preferred equity holders, providing for the conversion of all Series A and B Preferred Units into common units at an average conversion price of $3.12/unit.In connection with the recapitalization, ownership of the Partnership’s general partner, Mid-Con GP, LLC (the “General Partner”), has been transferred to the Partnership, resulting in strengthened corporate governance, and a new Board of Directors has been elected by written consent of the holders of a majority of the common unitholders.The Partnership also announced today the close of the spring redetermination of the borrowing base under its senior secured revolving credit facility (the “Credit...

Continue reading

Lord Global Corporation CEO details the company’s vision for its significant revenue and earnings growth for 2020 beyond

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) — The following is a letter to shareholders from Lord Global Corporation’s (OTC: LRDG) CEO:Dear fellow shareholders, I would like to take this opportunity to update all shareholders on our vision for Lord Global Corporation. The company intends to focus on the business development of its 27Health Inc. subsidiary. 27Health Inc. is dedicated to financing and marketing innovative, healthcare related products that are and will benefit from the permanent changes caused by the COVID-19 pandemic. It is our feeling that this crisis has accelerated the market share of direct to consumer healthcare products and services. Prior to the crisis, the direct to consumer cloud based market was among the fastest growing, subsequent to this crisis, we believe that 10 years worth of market share has been condensed...

Continue reading

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the following publications in peer-reviewed journals.The publication titled “Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial” has been published in Drugs in R&D and can be accessed here.The objective of this Phase 3 study was to evaluate the safety, tolerability and efficacy of IV tramadol 50 mg versus placebo in patients following abdominoplasty surgery, a soft-tissue surgical model. The study included an active comparator arm, IV morphine 4mg. While the study was not powered to provide statistical comparison of the...

Continue reading

XpresSpa Group Signs Contract with HyperPointe™ for Airport-based COVID-19 Screening and Testing

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has partnered with HyperPointe in connection with, XpresCheck, its newly formed business unit that will provide COVID-19 screening and testing in U.S. airports.Ezra T. Ernst, HyperPointe CEO, said, “We are extremely proud and excited to be working with XpresCheck in combatting this global pandemic and doing our part to help get the country back to normal. Airports serve as the gateway to our country, and ensuring their safety is a key step in getting us back to business as usual.”HyperPointe is providing a full range of support that extends far beyond marketing, according to Mr. Ernst.“We like to think of ourselves as co-pilots in helping XpresCheck launch this exciting...

Continue reading

Front Yard Residential Corporation Provides Operating Update

CHRISTIANSTED, U.S. Virgin Islands, June 05, 2020 (GLOBE NEWSWIRE) — Front Yard Residential Corporation (“Front Yard” or the “Company”) (NYSE: RESI) today reported the following operating metrics for April and May 2020:May collections at 30 days were 99% of the trailing 12-month historical average and April collections at 60 days were slightly ahead of the trailing 12-month historical average.Stabilized Rental leased percentage as of May 31, 2020 continued its positive trend at 98.2%, compared with 97.7% at April 30, 2020 and 97.0% at March 31, 2020.1Stabilized Rental April average occupied days were 95.5% compared to 93.5% a year ago, and May average occupied days were 96.1% compared to 92.7% a year ago.1Blended rent growth for both April and May was 3.9%.“Our primary concern has been and continues to be our residents, our employees...

Continue reading

Harsco to Participate in the Stifel 2020 Virtual Cross Sector Insight Conference

CAMP HILL, Pa., June 05, 2020 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC) announced today that Company management will participate in the Stifel 2020 Virtual Cross Sector Insight Conference on Wednesday, June 10. The Company will be represented by Chairman and CEO Nick Grasberger and Investor Relations Vice President Dave Martin. Updated presentation materials are available on the Company’s website at https://investors.harsco.com/.About Harsco Corporation Harsco Corporation is a global market leader providing environmental solutions for industrial and specialty waste streams and innovative technologies for the rail sector. Based in Camp Hill, PA, the 13,000-employee company operates in more than 30 countries. Harsco’s common stock is a component of the S&P SmallCap 600 Index and the Russell 2000 Index. Additional information...

Continue reading

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) — Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company’s messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.“We are excited to advance ARCT-810, a highly promising mRNA-based therapeutic candidate for OTC deficiency, into a Phase 1 study. This important milestone marks Arcturus’ transition into a clinical stage biopharmaceutical company,” said Steve Hughes, M.D., Chief Development Officer of Arcturus. “ARCT-810 is supported by compelling preclinical...

Continue reading

AgraFlora Takes Steps to Obtain Additional EU-GMP Quality Cannabis for German Distribution 

VANCOUVER, British Columbia, June 05, 2020 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc.  (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that on June 3, 2020, its wholly owned subsidiary Farmako GmbH (“Farmako”) has entered into a binding supply term sheet (the “Term Sheet”) with ZenPharm Ltd (“ZenPharm”),  a subsidiary of Zenabis Global Inc. (“Zenabis”) The Term Sheet serves as the basis to enter into a supply agreement which is expected to be completed in the coming weeks.Under the conditions of the Term Sheet, ZenPharm will supply EU-GMP quality medical cannabis flower cultivated by Zenabis to Farmako for distribution to medical cannabis patients in Germany.  The agreement is intended to facilitate the distribution of 1,500 kilograms of cannabis flower by Farmako...

Continue reading

AgraFlora prend des mesures afin d’obtenir plus de cannabis de qualité EU-GMP pour être distribué en Allemagne

VANCOUVER, Colombie-Britannique, 05 juin 2020 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc.  (« AgraFlora » ou la « Société ») (CSE : AGRA) (Frankfurt: PU31) (OTCPK : AGFAF) a le plaisir d’annoncer que le 3 juin 2020, sa filiale en propriété exclusive Farmako GmbH (« Farmako ») a conclu un accord d’approvisionnement contraignant (l’« Accord contraignant ») avec ZenPharm Ltd (« ZenPharm »), une filiale de Zenabis Global Inc (« Zenabis »). L’accord contraignant jette les bases à la conclusion d’un accord d’approvisionnement définitif qui devrait être finalisé dans les semaines à venir.Selon les termes de l’accord contraignant, ZenPharm fournira à Farmako des fleurs de cannabis médical de qualité EU-GMP cultivée par Zenabis pour être distribuées aux patients faisant usage de cannabis médical en Allemagne. L’accord vise à...

Continue reading

Sabina Gold & Silver Announces AGM Voting Results

VANCOUVER, British Columbia, June 05, 2020 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (TSX:SBB, OTCQX: SGSVF) (Sabina or the “Company”), in accordance with Toronto Stock Exchange requirements, is pleased to announce the voting results for election of its Board of Directors at its hybrid Annual General and Special Meeting of Shareholders held on June 4, 2020 in Vancouver, British Columbia. The director nominees as listed in the Management Information Circular dated April 22, 2020 were elected as directors of the Company at the meeting to serve until the next Annual General Meeting. In addition, the appointment of auditors as well as the Company’s adoption of new Articles were approved. The results are as follows:Total Eligible Votes: 298,213,292, Total Voted: 185,859,227 Total Voted %: 62.32%“On behalf of the Board of Directors,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.